1646

SA Form 10/30/02

PATENT
Attorney Reference No. 4239-61541

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Art Unit: 1646

Application No. 09/763,393

Filed: July 30, 2001

For: PAGE-4, AN X-LINKED GAGE-LIKE GENE EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS AND UTERUS, AND USES THEREFOR

Examiner: To be assigned

Date: October 30, 2002

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002, as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

Susan Alpert Siegel, Ph.D.
Agent for Applicant

TRANSMITTAL LETTER

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Enclosed for filing in the application referenced above are the following:

☒ Information Disclosure Statement
☒ Form 1449 and references cited thereon

☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By
Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.
Application No. 09/763,393
Filed: July 30, 2001
For: PAGE-4, AN X-LINKED GAGE-LIKE GENE EXPRESSED IN NORMAL AND NEOPLASTIC PROSTATE, TESTIS AND UTERUS, AND USES THEREFOR
Examiner: To be assigned
Date: October 30, 2002

Art Unit: 1646

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on October 30, 2002 as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Susan Alpert Siegel, Ph.D.
Agent for Applicant

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231

Sir:

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this Information Disclosure Statement, please charge any such fees, or credit overpayment, to Deposit

Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By _____
Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61541	App: 09/763,393
	Applicant: Pastan et al.	
	Filed: July 30, 2001	Art Unit:

U.S. PATENT DOCUMENTS

Init.*		Number	Date	Name	Class	Sub	Filed
		5,662,907	9/2/97	Kubo et al.			

OTHER DOCUMENTS

			Brinkmann, U. et al., *PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus*, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 10757-10762, (September 1998).
			Buus, S., *Description and prediction of peptide-MHC binding: the 'human MHC project'*, Curr. Opin. Immun., 11: 209-213 (1999).
			Celis, E. et al., *Epitope selection and development of peptide based vaccines to treat cancer*, Cancer Biology, Vol. 6, pp. 329-336 (1995).
			Celis, E. et al., *Induction of anti-tumor cytotoxic lymphocytes in normal humans using primary cultures and synthetic peptide epitopes*, Proc. Natl. Acad. Sci. USA, Vol. 91, pp. 2105-2109, (March 1994).
			Celis, E. et al., *Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles*, Molecular Immunology, Vol. 31, No. 18, pp. 1423-1430, (1994).
			Chesnut et al., *Design and Testing of Peptide-Based Cytotoxic T-Cell-Mediated Immunotherapeutics to Treat Infectious Diseases and Cancer,* Vaccine Design: The Subunit and Adjuvant Approach, Chapter 38, eds. Powell, M. and Newman, M., Plenum Press, New York (1995).
			Gulukota, K. et al., *Two Complementary Methods for Predicting Peptides Binding Major Histocompatibility Complex Molecules*, J. Mol. Biol., 1258-1267 (1997).
			Lanzavecchia, A., *Identifying Strategies for Immune Intervention*, Science, Vol. 260, pp. 937-944, (May 14, 1999).
			Rammensee, H. et al., *MHC ligands and peptide motifs: first listing*, Immunogentics, 41:178-228, (1995).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Docket: 4239-61541	App: 09/763,393
	Applicant: Pastan et al.	
	Filed: July 30, 2001	Art Unit:

			Schafer, J. et al., *Prediction of well-conserved HIV-1 ligands using a matrix based algorithm, EpiMatrix*, Vaccine, Vol. 16, No. 19, pp. 1880-1884 (1998).
			Sidney et al., *Broadly Reactive HLA Restricted T Cell Epitopes and Their Implications for Vaccine Design,* Concepts in Vaccine Development, Chapter 2, Ed. Kaufmann, S., Walter de Gryter, Berlin, New York (1996).
			Sinigaglia, F. and Hammer, J., *Motifs and Supermotifs for MHC Class II Binding Peptides*, J. Exp. Med., Vol. 181, pp. 449-451, (February 1995).
			Vasmatzis, G. et al., *Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis*, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 300-304 (January 1998).
			Vitiello, A. et al., *Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance*, Eur. J. Immunol., 27:671-678, (1997).

EXAMINER:	DATE

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.